Gastrointestinal stromal tumours (GIST);Tumeurs stromales du tube digestif (GIST)

Oncologie

Volumn 9, Issue 2, 2007, Pages 144-151

  Bui, B N ^a   Stoeckle E ^a   Kind, M ^a   Coindre, J M ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Diagnossis; Gastrointestinal stromal tumor; GIST; Imatinib; Prognosis; Sunitinib; Treatment

Indexed keywords

BCR ABL PROTEIN; EVEROLIMUS; IMATINIB; MIDOSTAURIN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR A; STEM CELL FACTOR; SUNITINIB;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; LIVER TOXICITY; LUNG TOXICITY; METASTASIS; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; NEPHROTOXICITY; PATIENT CARE; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34247545055     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-006-0552-6     Document Type: Article

References (41)

1. Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7: 507-19
2. Hirota S, Isozaki K, Moriyama Y, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-80
3. Heinrich MC, Corless CL, Duensing A, et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-10
4. Nilsson B, Bumming P, Meis-Kindblom JM, et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103: 821-9
5. Pidhorecky I, Cheney RT, Kraybill WG, et al. (2000) Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7: 705-12
6. Joensuu H (2006) Current perspectives on the epidemiology of gastrointestinal stromal tumours. EJC Suppl 4: 4-9
7. Rubin BP, Antonescu CR, Scott-Browne JP, et al. (2005) A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 65: 6631-9
8. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-25
9. Fletcher CD, Berman JJ, Corless C, et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-65
10. Duensing A, Heinrich MC, Fletcher CD, et al. (2004) Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest 22: 106-16
11. Demetri G, Benjamin R, Blanke CD (2006) NCCN risk force report: optimal management of patients with gastrointestinal stromal tumors (GIST). Expansion and Update of NCCN Clinical Practice Guidelines. J Natl Compr Cancer Netw 2: S1-S26
12. Blay JY, Landi B, Bonvalot S, et al. (2005) Recommendations for the management of GIST patients. Bull Cancer 92: 907-18
13. Wu PC, Langerman A, Ryan CW, et al. (2003) Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 134: 656-65
14. Gupta M, Sheppard BC, Corless CL, et al. (2006) Outcome following surgical therapy for gastrointestinal stromal tumors. J Gastrointest Surg 10: 1099-105
15. DeMatteo RP, Lewis JJ, Leung D, et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-8
16. Aparicio T, Boige V, Sabourin JC, et al. (2004) Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 30: 1098-103
17. Bauer S, Hartmann JT, de Wit M, et al. (2005) Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117: 316-25
18. Gronchi A, Fiore M, Bertulli R, et al. (2005) Surgery of residual disease following Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST). Proc ASCO 23 (abstract 9038)
19. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-6
20. Van Oosterom AT, Judson I, Verweij J, et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-3
21. Verweij J, van Oosterom A, Blay JY, et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006-11
22. Demetri GD, von Mehren M, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-80
23. Blanke CD, Demetri GD, von Mehren M, et al. (2006) Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. Proc ASCO 24 (abstract 9528)
24. Benjamin RS, Choi H, Macapinlac HA, et al. (2006) Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. Proc ASCO 24 (abstract 9506)
25. Lassau N, Lamuraglia M, Chami L, et al. (2006) Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol 187: 1267-73
26. Verweij J, Casali PG, Zalcberg J, et al. (2004) Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet 364: 1127-34
27. Rankin C, von Mehren M, Blanke C, et al. (2004) Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. Proc ASCO 22 (abstract 9005)
28. Debiec-Rychter M, Sciot R, Le Cesne A, et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-103
29. Debiec-Rychter M, Cools J, Dumez H, et al. (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128: 270-9
30. Heinrich MC, Corless CL, Demetri GD, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-9
31. Heinrich MC, Corless CL, Blanke CD, et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764-74
32. Judson I, Ma P, Peng B, et al. (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55: 379-86
33. Van Glabbeke M, Verweij J, Casali PG, et al. (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23: 5795-804
34. Blay JY, Berthaud P, Perol D, et al. (2004) Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. Proc ASCO 22 (abstract 9006)
35. Zalcberg JR, Verweij J, Casali PG, et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41: 1751-7
36. Demetri GD, Desai J, Fletcher JA, et al. (2004) SU11248, a multi-targeted tyrosinekinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc ASCO 22 (abstract 3001)
37. Demetri GD, van Oosterom AT, Garrett CR, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-38
38. Casali PG, Garrett CR, Blackstein ME, et al. (2006) Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. Proc ASCO 24 (abstract 9513)
39. Desai J, Yassa L, Marqusee E, et al. (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 660-4
40. Heinrich MC, Maki RG, Corless CL, et al. (2006) Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. Proc ASCO 24 (abstract 9502)
41. Benjamin R, Schöffski P, Hartmann JT, et al. (2006) Initial results of a multicenter single arm phase 2 study of AMG 706, an oral multikinase inhibitor, for the treatment of advanced imatinib-resistant gastrointestinal stromal tumors (GIST). 12th Annual CTOS Meeting, Venice November 2-4 (abstract 618)